CFDE Data Portal | Search LINC00504

	Label	Description
	LINC00504 Gene (Entity type)	ENSG00000248360 - long intergenic non-protein coding RNA 504
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE173483 nutlin-3 U2OS 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE95077 amiloride 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE135514 dasatinib 8 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS

LINC00504

ENSG00000248360 - long intergenic non-protein coding RNA 504

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE173483 nutlin-3 U2OS 1 v 0 human dn

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 6 human dn

A Gene Set from LINCS

GSE95077 amiloride 1 v 0 human up

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

A Gene Set from LINCS

GSE135514 dasatinib 8 v 9 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.